Search Results
Your search for ,New matches 16912 pages
Showing 10901 - 10950Recent Progress and Concepts in Pancreatic Cancer
November is National Pancreatic Cancer Awareness Month, the impetus for this article. Pancreatic cancer is a huge health challenge. It's the eighth most common cancer in the United States and the fourth most common cause of cancer deaths but is expected to become the second most common cause of...
Another Step Forward for Genomic Assays in Early-Stage Breast Cancer: Findings With MammaPrint in the MINDACT Trial
Genomic assays have had a powerful influence on the management of early-stage breast cancer, particularly estrogen receptor–positive tumors. The mainstay of adjuvant treatment for early-stage, hormone receptor–positive breast cancer has been endocrine therapy, either with tamoxifen and an...
Pembrolizumab as First-Line Therapy in Metastatic NSCLC: Practice-Changing Implications of KEYNOTE-024 Trial
We are in the midst of a paradigm shift in lung cancer. In the past 2 years, the anti–programmed cell death protein 1 (anti–PD-1) inhibitors nivolumab (Opdivo) and pembrolizumab (Keytruda) were found to improve overall survival in the second-line setting compared with docetaxel for patients with...
Pembrolizumab Improves Outcomes vs Platinum-Based Chemotherapy in Advanced PD-L1–Positive NSCLC
In the phase III KEYNOTE-024 trial reported in The New England Journal of Medicine by Martin Reck, MD, PhD, of the German Center of Lung Research, Grosshansdorf, and colleagues, pembrolizumab (Keytruda) significantly improved progression-free and overall survival vs platinum-based chemotherapy in...
Dafna Bar-Sagi, PhD, Receives NCI Outstanding Investigator Award
Cancer researcher Dafna Bar-Sagi, PhD, has made fundamental contributions to the understanding of the mechanisms that drive the disease. In recognition of her accomplishments, she has been named a recipient of the Outstanding Investigator Award, an honor presented by the National Cancer Institute...
Fred Hutch Opens Bezos Family Immunotherapy Clinic
Fred Hutchinson Cancer Research Center (Fred Hutch) has announced the official opening of a first-of-its-kind clinic dedicated to providing immunotherapies for cancer patients in clinical trials. The Bezos Family Immunotherapy Clinic, named in recognition of a family that has been deeply committed...
Phase III Trial Shows Improved PFS With Addition of Palbociclib to Letrozole in ER-Positive, HER2-Negative Breast Cancer
In the phase III PALOMA-2 trial reported in The New England Journal of Medicine, Finn et al found that the addition of palbociclib (Ibrance) to letrozole significantly improved progression-free survival in postmenopausal women with previously untreated advanced estrogen receptor–positive,...
ASCO’s TAPUR Study Has More Than 100 Participants Receiving Treatment Drugs and 25 New Clinical Trial Sites
More than 100 participants are now enrolled on study drug in ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) Study. The trial launched in March 2016 at 37 sites, and in November, it welcomed its newest participating clinical sites: Cancer Treatment Centers of America,...
New Study Links Obesity, Starting at Adolescence, to Endometrial Cancer Among Women Not Using Hormone Therapy
While it is well established that obesity is closely linked to endometrial cancer risk, most past findings have only looked at risk in relation to one measure of body size at a time. In a new study led by the Cancer Prevention Institute of California, published by Horn-Ross et al in Cancer Causes...
SITC Publishes First Kidney Cancer Treatment Guideline to Focus on Immunotherapy
The first evidence-based consensus statement on cancer immunotherapy for the treatment of patients with the most common type of kidney cancer, renal cell carcinoma, has been published by the Society for Immunotherapy of Cancer (SITC) in the Journal for ImmunoTherapy of Cancer by Rini et al. The...
Study Finds Cabozantinib of Clinical Benefit vs Sunitinib in Advanced Kidney Cancer
A randomized phase II clinical trial evaluating cabozantinib (Cabometyx) compared with standard-of-care sunitinib (Sutent) as first-line therapy for patients with advanced kidney cancer has found the experimental drug reduced the rate of disease progression or death by 34% compared with sunitinib....
New ALK Inhibitor, Brigatinib, Active in ALK-Rearranged Non–Small Cell Lung Cancer
In a phase I/II study reported in The Lancet Oncology, Gettinger et al found that the anaplastic lymphoma kinase (ALK) inhibitor brigatinib, which showed preclinical activity against ALK mutants resistant to crizotinib (Xalkori) and other ALK inhibitors, was active in patients with ALK-rearranged...
Study Describes Genetic Model of Pro-B ALL
After nearly 2 decades of unsuccessful attempts, researchers from the University of Chicago Medicine and the Cincinnati Children's Hospital Medical Center have created the first mouse model for the most common form of infant leukemia. Their discovery, reported by Lin et al in Cancer Cell, could...
SITC 2016: Immune Checkpoint Inhibitors Shrink Tumors in Some Patients With Metastatic Bladder Cancer
Combination immunotherapy is producing response rates ranging from 26% to 38% among patients with metastatic bladder cancer in the early stages of a three-arm clinical trial presented at the 2016 Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor, Maryland. “Until...
NAALADL2 Marker for Aggressive Prostate Cancer May Also Serve as a Drug Target
Researchers have discovered that a marker found on aggressive prostate cancer cells could also be used as a way to guide treatments to the cancer, according to new research presented by Luxton et al at the 2016 National Cancer Research Institute (NCRI) Cancer Conference in Liverpool, United...
Blocking ADAM17 Protein May Help to Circumvent Resistance to Cetuximab in Bowel Cancer
Blocking a molecule may bypass bowel cancer's defense against the drug cetuximab, according to new research presented by Weir et al at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool, United Kingdom. Cetuximab is used to treat advanced bowel cancer, and just under half ...
Does Telotristat Ethyl Reduce the Frequency of Bowel Movements in Patients With Metastatic NETs and Carcinoid Syndrome?
In the phase III TELESTAR trial reported in the Journal of Clinical Oncology by Kulke et al, telotristat ethyl, a tryptophan hydroxylase inhibitor, significantly reduced the frequency of bowel movements in patients with metastatic neuroendocrine tumors and carcinoid syndrome. Telotristat ethyl...
Christine Mayr, MD, PhD, of Sloan Kettering Institute, Honored With NIH Director’s Pioneer Award
Molecular biologist Christine Mayr, MD, PhD, of Memorial Sloan Kettering’s Sloan Kettering Institute is among this year’s 12 recipients of the prestigious National Institutes of Health (NIH) Director’s Pioneer Award. Established in 2004, the annual award recognizes and supports individual...
José R. Conejo-Garcia, MD, PhD, Joins Moffitt as Co-Leader of Immunology Program, Chair of Department of Immunology
José R. Conejo-Garcia, MD, PhD, has joined Moffitt Cancer Center as Coleader of the Immunology Program and Chair of the Department of Immunology. The Immunology Program is focused on defining the regulation role of immune checkpoint molecules in tumor immune surveillance and in identifying new...
Living With Metastatic Breast Cancer Is Like Walking a Tightrope
I’ve always had fibrocystic breasts and was steadfast in performing monthly breast self-exams, so I could become familiar with the terrain of my breasts and spot any subtle changes. So, in November 2002, when I felt something in my left breast that seemed different from my usual lumps, I made a...
Meta-analysis Identifies New Genetic Variants for Barrett’s Esophagus and Esophageal Adenocarcinoma
As reported in The Lancet Oncology, Puya Gharahkhani, PhD, of QIMR Berghofer Medical Research Institute, Brisbane, Australia, and colleagues identified several new genetic risk variants for the development of Barrett’s esophagus and esophageal adenocarcinoma through a large-scale meta-analysis of...
Medical Marijuana: The Topic You Can’t Escape
With reports about new marijuana dispensaries sprouting up as more states approve the legal use of medical marijuana, and patients and family members questioning how to get it, medical marijuana is a “topic you can’t escape,” noted Judith A. Paice, PhD, RN.1 Dr. Paice is Director of the Cancer...
The Smartest Guys in the Room
The smartest guys in the room were never from the big energy companies, and they’re not running hedge funds on Wall Street or building the next Facebook. For me, the smartest guys in the room are the selfless men and women who’ve transformed cancer from what was all too often a death sentence to...
Advanced Practitioners Convene for Annual JADPRO Live at APSHO Meeting
The fourth annual JADPRO Live conference was held recently in conjunction with the Annual Meeting of the Advanced Practitioner Society for Hematology and Oncology (APSHO) on November 3–6, 2016, at the Gaylord National Hotel in National Harbor, Maryland. More than 1,100 individuals attended...
2016-2017 Oncology Meetings
NOVEMBER 21st Annual Perspectives in Thoracic OncologyNovember 18-19 • New York, New YorkFor more information:http://imedex.com/perspectives-thoracic-oncology-conference/index.asp Mayo Clinic Angiogenesis and Tumor Microenvironment Symposium: From Translational Research to Clinical Practice...
Resuscitation During Surgery
During the 1890s, aseptic principles were extended only to the operative area of the patient, not the surgeon, although some surgeons did advocate the use of special white or colored uniforms, and hand washing had already been established. In 1895, just 7 years after Arpad Gerster, MD, published...
Enrollment Completed for Phase III ECHELON-2 Clinical Trial Evaluating Front-Line Brentuximab Vedotin in Mature T-Cell Lymphoma
Seattle Genetics, Inc, and Takeda Pharmaceutical Company Limited have announced completion of patient enrollment in the ECHELON-2 clinical trial. ECHELON-2 is a global phase III randomized trial evaluating brentuximab vedotin (Adcetris) as part of a front-line combination chemotherapy regimen in...
Let’s Win: Innovative Online Community Offers Guidance to Patients With Pancreatic Cancer and Their Families
Let’s Win is an online community for persons with pancreatic cancer (www.letswinpc.org), but it is far more than a typical support group. Let’s Win propels interested users toward cutting-edge research, based on its founders’ commitment that no patient with pancreatic cancer should settle on the...
New Blood Test for Colorectal Cancer Recurrence: Twice as Sensitive as CEA Test
In a new report published by Young et al in Cancer Medicine,1 a two-gene circulating tumor DNA (ctDNA) blood test for postsurgical monitoring of colorectal cancer recurrence has been shown to detect twice the number of recurrence cases as carcinoembryonic antigen (CEA) testing, a standard-of-care...
Modified Indication for Erlotinib in Advanced Non–Small Cell Lung Cancer
On October 18, 2016, the indication for erlotinib (Tarceva) in the treatment of non–small cell lung cancer (NSCLC) was modified to limit use to patients with tumors with specific epidermal growth factor receptor (EGFR) mutations in maintenance or second- or greater-line treatment; these mutations...
Suresh S. Ramalingam, MD, Honored With Goizueta Chair for Cancer Research at Winship Cancer Institute
Suresh S. Ramalingam, MD, Deputy Director of Winship Cancer Institute of Emory University and Assistant Dean for Cancer Research in the Emory School of Medicine, was honored with the Roberto C. Goizueta Distinguished Chair for Cancer Research. The endowment was established to support a key leader...
Kwok-Kin Wong, MD, PhD, to Join NYU Langone as Chief of Hematology and Medical Oncology
The Perlmutter Cancer Center at New York University (NYU) Langone Medical Center has named clinician-scientist Kwok-Kin Wong, MD, PhD, as its new Chief of Hematology and Medical Oncology. His recruitment promises to transform the medical center’s research and clinical programs in lung cancer and...
Fox Chase Cancer Center Designated as a National Pancreas Foundation Center
Fox Chase Cancer Center has been designated as a National Pancreas Foundation Center by the National Pancreas Foundation (NPF), a nonprofit organization that provides hope for those suffering from pancreatic cancer and other pancreas-related diseases. Fox Chase is the only institution in the...
Diagnosing and Managing Chemotherapy-Induced Peripheral Neuropathy
Chemotherapy-induced peripheral neuropathy is a common side effect of cancer treatment—the incidence is reported to be as high as 70% in the first month of chemotherapy1—and can cause significant disability in patients. The extent of the neurotoxicity incurred by patients varies depending on the...
CDC Recommends Only Two HPV Shots for Younger Adolescents
The Centers for Disease Control and Prevention (CDC) have recommended that 11- to 12-year-olds receive 2 doses of human papillomavirus (HPV) vaccine at least 6 months apart rather than the previously recommended 3 doses to protect against cancers caused by HPV infections. Teens and young adults who ...
Dana-Farber Cancer Institute, CPDC at McMaster University Join to Speed Cancer Research With Molecular Probes
Dana-Farber Cancer Institute and the Centre for Probe Development and Commercialization (CPDC) at McMaster University in Hamilton, Ontario, Canada, will work together to create novel molecular probes for noninvasive imaging in cancer research, drug development, and patient care. The two leading...
Cardio-oncology in the Geriatric Patient
As cancer therapies improve and the population as a whole increases, there are rising numbers of elderly patients with cancer. More than half of patients newly diagnosed with cancer are aged 65 years or older.1 In January 2012, it was estimated that more than 8 million cancer survivors were over...
Use Social Media to Stay Up-to-Date on New Patient Materials From Cancer.Net
Encourage your patients to use social media for details on the newest resources available on Cancer.Net. It is easier than ever for patients to get the latest cancer information on their computer or mobile device by subscribing to the Cancer.Net Blog at www.cancer.net/blog or on Cancer.Net’s...
ASCO Introduces Two New Journals: JCO Precision Oncology and JCO Clinical Cancer Informatics
ASCO is excited to launch two new online-only journals, JCO Precision Oncology (JCO PO) and JCO Clinical Cancer Informatics (JCO CCI). Both journals will be exploring the latest topics in oncology and filling a void for the oncology community. Manuscripts will go through the traditional peer-review ...
Interviews With ASCO’s President-Elect Candidates
ASCO Connection: Why do you want to serve as ASCO President? Monica Bertagnolli: Serving as ASCO President is a tremendous personal honor for anyone in the field of oncology. Much more importantly, it is an opportunity to make a meaningful difference by providing a strong voice in the health-care ...
As More Biosimilars Move Toward U.S. Market, Questions Remain About Cost Savings and Uptake by Physicians and Patients
The U.S. Food and Drug Administration (FDA) approved its first biosimilar drug, filgrastim-sndz (Zarxio), in 2015, allowing it to compete with the granulocyte colony-stimulating factor filgrastim (Neupogen) to treat neutropenia in chemotherapy patients. So far, filgrastim-sndz is the only...
Ellen and Gary Davis Immune Monitoring Core Established at Weill Cornell Medicine
With the goal of advancing a powerful cancer treatment strategy that uses immune cells to fight the disease, benefactors Ellen and Gary Davis have made a $2 million gift to Weill Cornell Medicine to drive ongoing research in immunotherapy, the institution announced. This gift will launch the Ellen...
Charles S. Fuchs, MD, MPH, to Lead Yale Cancer Center and Smilow Cancer Hospital
Smilow Cancer Hospital at Yale New Haven and Yale Cancer Center (YCC) have announced that Charles S. Fuchs, MD, MPH, will become the new Director and Physician-in-Chief at Smilow Cancer Hospital at Yale New Haven, effective January 1, 2017. Dr. Fuchs will be taking the reins of the Smilow Cancer...
Florida Atlantic University Appoints Phillip M. Boiselle, MD, as Dean of the Charles E. Schmidt College of Medicine
Florida Atlantic University has named Phillip M. Boiselle, MD, as the new Dean of the Charles E. Schmidt College of Medicine. Dr. Boiselle, who currently serves as Associate Dean for Academic and Clinical Affairs and Professor of Radiology at Harvard Medical School, and is a member of the...
Roger Stupp, MD, Appointed Associate Director for Strategic Initiatives at Robert H. Lurie Cancer Center
Swiss neuro-oncologist Roger Stupp, MD, has been appointed Associate Director for Strategic Initiatives at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. A leading authority on the treatment of primary and metastatic brain cancer, Dr. Stupp will join Northwestern...
Chemotherapy May Be Avoidable in Some Women With Early-Stage Breast Cancer Based on Clinical and Genomic Risks
In the phase III MINDACT trial reported in The New England Journal of Medicine, Fatima Cardoso, MD, of Champalimaud Clinical Center–Champalimaud Foundation, Lisbon, and colleagues found that adjuvant chemotherapy may be avoidable in women with early-stage breast cancer who are at high clinical...
FDA Grants Accelerated Approval to Olaratumab for Treatment of Advanced Soft-Tissue Sarcoma
Today, the U.S. Food and Drug Administration (FDA) granted accelerated approval to olaratumab (Lartruvo) in combination with doxorubicin to treat adults with certain types of soft-tissue sarcoma. Olaratumab is approved for use with the FDA-approved chemotherapy drug doxorubicin for the treatment...
Gold Nanoparticle Radiopharmaceuticals for the Selective Treatment of Telomerase-Positive Tumors
Tagging gold nanoparticles with a small dose of radiation has helped researchers trace the precious metal as it delivers a drug right into the heart of cancer cells, according to new laboratory research presented by Bavelaar et al at the 2016 National Cancer Research Institute (NCRI) Cancer...
Is Observation Without Surgery a Viable Strategy for Managing Ductal Carcinoma in Situ?
In a spirited debate, abounding with citations of clinical trials and other evidence, but not without humor and mutual respect, E. Shelley Hwang, MD, MPH, and Armando E. Giuliano, MD, reviewed the data and their clinical experience managing ductal carcinoma in situ and reached opposite...
1 in 6 Women Diagnosed With Breast Cancer Have a Symptom Other Than a Lump
Around one in six women (17%) diagnosed with breast cancer go to their doctor with a symptom other than a lump—the most commonly reported breast cancer symptom—according to new research presented by Koo et al at the 2016 National Cancer Research Institute (NCRI) Cancer Conference in...
